VNDA Vanda Pharmaceuticals Inc.
USHealthcareAs of 2026-08-24
Why VNDA matters now
Vanda Pharmaceuticals Inc. (VNDA) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.33 with +0.95% on the session and $320.5M in market capitalization; recent performance reads 1-month -3.17% and YTD -34.24%.
The latest financial table shown here is Q1 2026, with revenue of $51.7M, net income of $-48.6M, and EPS of $-0.82. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -36.5%.
The latest indexable market news headline is "Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $14.25; recent insider activity includes McGuire Daniel Patrick filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.23
P/S
1.60
EV/EBITDA
-2.26
DCF Value
$-1.74
FCF Yield
-36.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.5%
Operating Margin
-73.6%
Net Margin
-110.0%
ROE
-61.4%
ROA
-55.3%
ROIC
-52.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $51.7M | $-48.6M | $-0.82 |
| Q4 2025 | $57.2M | $-141.2M | $-2.39 |
| FY 2025 | $216.1M | $-220.5M | $-3.74 |
| Q3 2025 | $56.3M | $-22.6M | $-0.38 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$14.25
Target (Median)
$14.25
Target Range
$7.50 - $21.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.60
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.